The company has a portfolio of vaccines under research including
Ad5-EBOV to prevent
Ebola and
Ad5-nCoV for
COVID-19. The company has previously collaborated with the
National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.
COVID-19 vaccine development '' vaccine for COVID-19 (AD5-nCOV)
filled and finished in Mexico. AD5-nCOV, trade-named Convidecia, is a single-dose
viral vector COVID-19 vaccine developed by CanSino. Since late 2020, it has been in
Phase III trials in
Chile,
Mexico,
Pakistan,
Russia, and
Saudi Arabia It has similar efficacy to the
Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial. In April 2021, CanSino Biologics began clinical trials for a version of its COVID-19 vaccine administered by inhalation rather than injection. Rollout of inhaled boosters began in China in October 2022. Convidecia is approved for use by some countries in Asia, Latin America, and by Hungary. Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China, Malaysia, and
Pakistan. == Investors ==